Heading
<h3> Absolute Contraindications of Amaltas/Aragvadha (Cassia fistula) </h3> <h4> Pregnancy / Active pregnancy (in which you are carrying a baby)</h4> <ul> <li> 🤰 <li> Recommendation: Avoid Amaltas-containing stimulant preparations during pregnancy unless a qualified clinician advises and monitors use; prefer safer alternatives for constipation. <li> Reasoning: Anthraquinone cathartics cross the placenta and reach the fetus; stimulant laxatives may cause uterine irritation and fetal exposure, and animal data show effects on offspring growth at higher doses. <li> Scientific_Study_Title: Fetal exposure to 1:8 dihydroxyanthraquinone. <li> Scientific_Study_Authors: A W Blair, M Burdon, J Powell, M Gerrard, R Smith <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/911960/ <li> Scientific_Study_Excerpt: <p>The authors surveyed maternity cases and measured maternal and fetal exposure to a model anthraquinone cathartic. They found that the compound is absorbed from the maternal gut, crosses the placenta, and is excreted by the fetal kidneys into the amniotic fluid. In mothers and babies most of the substance appeared as glucuronide conjugates, demonstrating systemic maternal absorption and fetal exposure. The study noted that fetal catharsis did not occur despite fetal exposure, but it established that anthraquinone laxatives administered to pregnant women reach the fetus - a pharmacokinetic basis for caution in pregnancy with stimulant laxative herbs containing anthraquinone derivatives.</p> <p>Because Amaltas pods are a source of anthraquinones (e.g., rhein), this report supports avoiding such preparations in pregnancy to prevent fetal exposure and possible uterine or fetal effects.</p> </li> </ul> <h4> Severe liver disease / Decompensated hepatic impairment </h4> <ul> <li> 🩺 <li> Recommendation: Do not use concentrated or long-term Amaltas extracts if you have significant liver disease; consult a hepatologist before any herbal use. <li> Reasoning: Animal subchronic dosing studies of Cassia fistula extracts have shown dose-related liver enzyme changes and histological hepatic inflammation at higher sustained doses, indicating potential hepatotoxicity risk with large or prolonged intake. <li> Scientific_Study_Title: Antibacterial activity and subchronic toxicity of Cassia fistula L. barks in rats. <li> Scientific_Study_Authors: Anis Yohana Chaerunisaa, Yasmiwar Susilawati, Muhaimin Muhaimin, Tiana Milanda, Rini Hendriani, Anas Subarnas <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/32461915/ <li> Scientific_Study_Excerpt: <p>In this study investigators evaluated antibacterial effects of ethanol extracts of C. fistula bark and conducted a 90-day subchronic toxicity assessment in rodents. While antibacterial efficacy was demonstrated, repeated exposure at higher doses (notably 1000 mg/kg) produced histological changes in liver tissue and biochemical perturbations consistent with hepatic stress; some of these changes resolved after a recovery period. The authors concluded that while extracts have therapeutic potential, high-dose or prolonged exposure may induce reversible hepatic and renal histopathology, and they recommended cautious dosing-preferably below the doses that produced toxicity in animals-when considering therapeutic use.</p> <p>This evidence supports avoiding concentrated or prolonged use in patients with pre-existing, especially decompensated, liver disease.</p> </li> </ul> <h4> Severe kidney disease / Advanced renal impairment</h4> <ul> <li> 🩸 <li> Recommendation: Avoid stimulant anthraquinone preparations like Amaltas in patients with advanced kidney disease or unstable renal function unless supervised by a clinician experienced in herbal-pharmacology. <li> Reasoning: Animal pregnancy and toxicity studies with C. fistula extracts have documented changes in renal histomorphometry (Bowman's capsule changes, malpighian body area) and dose-related biochemical effects, indicating potential renal stress at higher doses. <li> Scientific_Study_Title: Effect of Cassia fistula L. aqueous extract in maternal reproductive outcome, some serum indices and fetal anomaly frequency in rat. <li> Scientific_Study_Authors: Saeed Hakiminia, Zahra Esmaeeli, Ali Akbar Moghadamnia, Seyyed Gholam Ali Jorsaraei, Farideh Feizi, Sorayya Khafri, Zahra Memariani, Hoda Shirafkan, Seyyed Ali Mozaffarpur <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35974950/ <li> Scientific_Study_Excerpt: <p>Pregnant rats received oral Cassia fistula aqueous extract at graded doses throughout gestation. While gross teratogenic effects or abortions were not observed, the investigators recorded dose-dependent reductions in offspring weight and histopathological changes in multiple organs. Notably, renal histomorphometry showed significant increases in malpighian body area and Bowman's capsule space compared with controls. Higher dose groups also showed biochemical enzyme changes and signs of hepatic parenchymal inflammation. The authors advised caution, highlighted possible confounders in some findings, and called for additional research, but the renal structural changes support caution in patients with impaired kidney function.</p> </li> </ul> <h4> Known allergy / hypersensitivity to Cassia species or anthraquinone-containing plants </h4> <ul> <li> ⚠️ <li> Recommendation: If you have a history of allergic reactions (skin rash, rhinitis, conjunctivitis, bronchial symptoms) to senna/cassia-family products or plant-derived quinones, avoid Amaltas preparations and seek allergy testing/medical advice. <li> Reasoning: Plants containing anthraquinones or related quinone structures can sensitize and provoke IgE-dependent and contact-allergic reactions; occupational and case reports confirm respiratory and skin hypersensitivity to Cassia species. <li> Scientific_Study_Title: Exploring a rare case of occupational senna allergy. <li> Scientific_Study_Authors: L Carneiro-Leão, L Amaral, D Silva, B Bartolomé, M Miranda <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/30496499/ <li> Scientific_Study_Excerpt: <p>This case report documents an occupational IgE-mediated allergy to senna (a Cassia species). A warehouse worker developed immediate bronchial, conjunctival and nasal symptoms when exposed to senna; investigators demonstrated in vitro IgE binding proteins and confirmed sensitization with positive skin tests and conjunctival provocation. The report establishes that Cassia-family plants can act as occupational sensitizers and produce respiratory and ocular allergy via IgE-mediated mechanisms. While rare, such reactions provide clear evidence to avoid Cassia products in sensitized individuals and to consider occupational exposure risks.</p> </li> </ul> <h3> Relative Contraindications of Amaltas/Aragvadha (Cassia fistula) </h3> <h4> Concurrent use with cardiac glycosides (e.g., digoxin)</h4> <ul> <li> ❤️ <li> Interaction_Details: Stimulant laxatives can cause or worsen hypokalemia; low potassium increases the risk of digoxin toxicity and abnormal heart rhythms. <li> Severity: Severe <li> Recommendation: Avoid unsupervised use of Amaltas if you take digoxin; if considered necessary, obtain close medical monitoring of electrolytes and digoxin levels. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/32672366/ <li> Scientific_Study_Title: Adverse drug event of hypokalaemia-induced cardiotoxicity secondary to the use of laxatives: A systematic review of case reports. <li> Scientfic_Study_Authors: Safeer Khan, Shafi Ullah Khan <li> Scientific_Study_Excerpt: <p>This systematic review collected 27 case reports (1995-2019) where laxative-induced electrolyte disturbance led to cardiac toxicity. Nearly half presented with severe hypokalaemia; 70% had electrocardiographic changes typical of hypokalemia and a subset developed serious arrhythmias - two deaths were reported. The review highlights situations where laxative abuse, co-medications, or underlying diseases amplified risk. Because stimulant anthraquinone laxatives (the class that includes Cassia-containing products) are represented among implicated agents, the authors recommend that clinicians consider laxative use when evaluating unexplained hypokalemic cardiac events and avoid combining stimulant laxatives with drugs that have narrow therapeutic windows affected by electrolytes, such as digoxin.</p> </li> </ul> <h4> Concomitant use with potassium-wasting diuretics or other drugs causing electrolyte loss</h4> <ul> <li> 💊 <li> Interaction_Details: Laxative-induced diarrhea can worsen potassium and volume loss, which is additive with diuretics and can destabilize blood pressure and heart rhythm. <li> Severity: Moderate <li> Recommendation: Use with caution; monitor electrolytes and renal function if combined, and avoid combined chronic use without clinician supervision. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/6603084/ <li> Scientific_Study_Title: Digoxin toxicity and electrolytes: a correlative study. <li> Scientfic_Study_Authors: (Authors listed in paper: see PubMed record) - (H. Humber J.M. et al. / note: study demonstrates role of electrolytes in digoxin toxicity) <li> Scientific_Study_Excerpt: <p>This clinical correlation study examined serum electrolytes and digoxin levels in patients with digitalis toxicity. It showed that hypokalemia is a frequent and important cofactor in the development of digoxin toxicity; many patients with toxicity had significantly lower serum potassium levels. The paper highlights how therapies (diuretics or other causes of potassium loss) that reduce potassium can precipitate arrhythmias and digitalis adverse events even when drug levels are within expected ranges. By extension, stimulant laxatives that increase GI potassium losses can similarly raise risk when combined with potassium-wasting medications.</p> </li> </ul> <h4> Long-term or chronic use (risk of melanosis coli / possible colorectal effects)</h4> <ul> <li> ⚠️ <li> Interaction_Details: Chronic anthraquinone laxative use has been associated in observational data with pigmentary changes in the colon (melanosis coli) and a debated possible association with colorectal cancer risk. <li> Severity: Moderate <li> Recommendation: Avoid long-term daily use of Amaltas as a stimulant laxative; prefer lifestyle, bulk-forming or osmotic approaches and seek medical review for chronic constipation. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35040201/ <li> Scientific_Study_Title: Anthraquinone laxatives use and colorectal cancer: A systematic review and meta-analysis of observational studies. <li> Scientfic_Study_Authors: (See paper authors on PubMed) <li> Scientific_Study_Excerpt: <p>The systematic review and meta-analysis pooled observational studies evaluating the relationship between anthraquinone laxative use and colorectal cancer risk. Although the pooled estimate suggested a trend toward increased risk (OR ~1.4) when comparing anthraquinone users with non-users, the association did not reach robust statistical significance and evidence quality was moderate-to-low. The authors concluded that evidence is inconclusive but highlighted a consistent trend that justifies caution and further high-quality research. Given that Cassia fistula is an anthraquinone-containing plant, prudent avoidance of long-term stimulant use is advised.</p> </li> </ul> <h4> Use with narrow therapeutic index immunosuppressants (e.g., tacrolimus) or P-gp/CYP substrates</h4> <ul> <li> 🧪 <li> Interaction_Details: Cassia-family herbal products may change intestinal transport or metabolism (P-glycoprotein/CYP) or alter absorption through increased gut motility; case reports show substantial increases in tacrolimus exposure after concomitant Cassia product intake. <li> Severity: Severe <li> Recommendation: Avoid co-use with tacrolimus/cyclosporine or other drugs with narrow therapeutic indices unless therapeutic drug monitoring and specialist oversight are available. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/38657592/ <li> Scientific_Study_Title: Cassia angustifolia and tacrolimus interaction in a liver transplant patient, a case report. <li> Scientfic_Study_Authors: Iván Beltrá-Picó, Marcos Díaz-González, Ricardo Nalda-Molina, Amelia Ramon-Lopez, Sonia Pascual-Bartolomé, Cayetano F Miralles-Macià, María Rodríguez-Soler, Patricio Más-Serrano <li> Scientific_Study_Excerpt: <p>This 2024 case report documents a liver transplant patient who took a herbal product based on Cassia angustifolia alongside tacrolimus and experienced a marked increase in tacrolimus blood concentration (2.8-fold rise in trough levels, 2.1-fold AUC). The authors suggest an herb-drug interaction likely via intestinal transporter (P-glycoprotein) modulation or altered absorption from increased gut motility. Given tacrolimus's narrow therapeutic window and dose-related nephrotoxicity and neurotoxicity, this interaction is clinically important and supports avoiding Cassia products with critical-dose immunosuppressants without intensive monitoring.</p> </li> </ul>
Heading
<h4> Abdominal cramping and diarrhea (short-term)</h4> <ul> <li> 🤢 <li> Side effect summary: Users commonly experience abdominal cramps, urgency, and watery stools after stimulant laxative doses; these are dose-related and usually resolve when the herb is stopped. <li> Recommendation: Start with low dose, avoid bedtime dosing that may cause nighttime urgency, and stop use if severe cramping or dehydration occurs; seek medical care if prolonged diarrhea or blood appears. <li> Reasoning: Stimulant anthraquinones accelerate colonic transit and secretions, which can produce cramping and loose stools; clinical reviews of laxatives document these common effects. <li> Severity Level: Mild <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Adverse effects of laxatives. <li> Scientific_Study_Authors: (See PubMed record) <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/11535863/ <li> Scientific_Study_Excerpt: <p>Reviewing adverse effects across laxative classes, the authors note that stimulant laxatives (such as senna-like anthraquinone products) commonly cause abdominal discomfort, cramping, and diarrhea. While generally safe when used intermittently and at recommended doses, stimulant laxatives can produce more notable side effects at higher doses or with prolonged use. The review contrasts stimulant laxatives with bulk-forming and osmotic agents and emphasizes tailored selection and monitoring for vulnerable patients.</p> </li> </ul> <h4> Hypokalemia and downstream cardiac effects (arrhythmia risk)</h4> <ul> <li> 💔 <li> Side effect summary: Excessive or prolonged stimulant laxative use can cause loss of potassium, which can lead to muscle weakness, palpitations, and serious heart rhythm disturbances. <li> Recommendation: Avoid large or chronic doses; monitor electrolytes if repeated use is required; seek urgent care for palpitations, dizziness or fainting. <li> Reasoning: Case reports and systematic reviews show that laxative-induced electrolyte loss can precipitate severe cardiac events, sometimes fatal, especially when combined with other risk factors or medications. <li> Severity Level: Severe <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Adverse drug event of hypokalaemia-induced cardiotoxicity secondary to the use of laxatives: A systematic review of case reports. <li> Scientific_Study_Authors: Safeer Khan, Shafi Ullah Khan <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/32672366/ <li> Scientific_Study_Excerpt: <p>The systematic review aggregated 27 case reports in which laxative use led to hypokalaemia and associated cardiotoxic events. Many patients had severe hypokalaemia with ECG changes, arrhythmias, or cardiac compromise; two deaths were recorded. Factors contributing to risk included laxative abuse, concurrent medications, and underlying diseases. Because anthraquinone-containing herbal laxatives (the plant category that includes C. fistula) were represented, the review emphasizes careful use and monitoring for electrolyte disturbances in people using stimulant herbal laxatives.</p> </li> </ul> <h4> Liver or kidney enzyme changes with high/long-term dosing</h4> <ul> <li> 🧾 <li> Side effect summary: High doses or prolonged usage in animals produced liver enzyme elevations and histologic inflammation and some kidney structural changes; human data are limited but caution is warranted. <li> Recommendation: Avoid high-dose or long-term self-administration; check LFTs and renal function if prolonged therapy is considered. <li> Reasoning: Subchronic animal experiments found reversible liver and kidney histopathology after sustained high-dose exposure to C. fistula extracts. <li> Severity Level: Moderate <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Antibacterial activity and subchronic toxicity of Cassia fistula L. barks in rats. <li> Scientific_Study_Authors: Anis Yohana Chaerunisaa, Yasmiwar Susilawati, Muhaimin Muhaimin, Tiana Milanda, Rini Hendriani, Anas Subarnas <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/32461915/ <li> Scientific_Study_Excerpt: <p>During a 90-day study, high-dose C. fistula bark extract showed antibacterial efficacy but also produced histological liver and kidney alterations at the highest tested doses (1000 mg/kg); some changes normalized after a recovery period. The authors concluded that while extracts have therapeutic effects, prolonged high-dose exposure may cause reversible organ changes and recommended dose control and monitoring when moving toward therapeutic use.</p> </li> </ul> <h4> Pigmentation of the colon (melanosis coli) and debated long-term colorectal risk </h4> <ul> <li> 🧾 <li> Side effect summary: Chronic anthraquinone laxative users can develop melanosis coli (dark pigmentation of colonic mucosa); long-term association with colorectal cancer is debated but has shown trend signals in observational studies. <li> Recommendation: Avoid chronic daily use. Use alternative safer long-term strategies (fiber, osmotic laxatives, lifestyle) and consult a clinician for persistent constipation. <li> Reasoning: Systematic reviews of observational studies show a non-definitive trend toward increased colorectal risk with long-term anthraquinone exposure; mechanistic and epidemiologic data are mixed, so prudence is advised. <li> Severity Level: Mild <li> Scientific_Study_Available: Yes <li> Scientific_Study_Title: Anthraquinone laxatives use and colorectal cancer: A systematic review and meta-analysis of observational studies. <li> Scientific_Study_Authors: (See PubMed record) <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35040201/ <li> Scientific_Study_Excerpt: <p>This meta-analysis pooled observational studies of anthraquinone laxative use and colorectal cancer. The summary estimate suggested a trend toward increased risk (OR ≈1.4) but did not achieve strong statistical significance; study quality and heterogeneity limit certainty. The authors recommend that, given the persistent signal, clinicians and patients avoid unnecessary chronic use and prioritize safer long-term management strategies for constipation.</p> </li> </ul>
Heading
<h4> Cardiac glycosides (e.g., digoxin)</h4> <ul> <li> Interaction_Details: Stimulant laxatives can produce hypokalemia and electrolyte shifts that increase risk of digoxin toxicity and arrhythmias; laxative-induced diarrhea can also reduce drug absorption unpredictably. <li> Severity: Severe <li> Recommendation: Avoid unsupervised use with digoxin. If use is unavoidable, monitor serum potassium and digoxin levels closely and adjust therapy under physician supervision. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/32672366/ <li> Scientific_Study_Title: Adverse drug event of hypokalaemia-induced cardiotoxicity secondary to the use of laxatives: A systematic review of case reports. <li> Scientfic_Study_Authors: Safeer Khan, Shafi Ullah Khan <li> Scientific_Study_Excerpt: <p>The systematic review of case reports documents that laxative-driven hypokalaemia contributed to cardiac toxicity, including ECG changes, arrhythmias and deaths. Multiple reports implicated stimulant laxatives or herbal laxatives. Because serum potassium is a critical determinant of digoxin safety (hypokalemia potentiates toxicity), the review supports strong caution and monitoring when stimulant laxatives are used concurrently with digoxin.</p> </li> </ul> <h4> Potassium-wasting diuretics (e.g., furosemide, thiazides)</h4> <ul> <li> Interaction_Details: Additive potassium loss from laxative-associated diarrhea and diuretic renal loss can precipitate symptomatic hypokalemia and related cardiac or muscular issues. <li> Severity: Moderate <li> Recommendation: Avoid combined unsupervised long-term use; monitor electrolytes frequently and consider potassium supplementation if clinically indicated after medical review. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/6603084/ <li> Scientific_Study_Title: Digoxin toxicity and electrolytes: a correlative study. <li> Scientfic_Study_Authors: (Authors as listed in PubMed record) <li> Scientific_Study_Excerpt: <p>This clinical study correlates electrolyte disturbances (notably low potassium) with increased risk of digoxin toxicity and related cardiac events. It highlights that medications or conditions causing potassium loss (including diuretics and GI losses) materially increase the risk of cardiotoxicity from drugs whose safety depends on normal serum electrolytes. The physiologic principle generalizes to combinations of laxatives and diuretics, supporting monitoring and caution.</p> </li> </ul> <h4> Vitamin K antagonists / Warfarin</h4> <ul> <li> Interaction_Details: Excessive laxative-induced diarrhea can alter vitamin K absorption and fluid balance, and case reports associate senna-like herb overuse with elevated INR and bleeding. <li> Severity: Moderate <li> Recommendation: Avoid chronic high-dose use with warfarin; if used, monitor INR more frequently while starting, stopping or changing doses of the herbal product. <li> Scientific_Study_Available: Yes (case reports) <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/18313506/ <li> Scientific_Study_Title: Near-fatal bleeding, senna, and the opposite of lettuce. <li> Scientfic_Study_Authors: Weekitt Kittisupamongkol, Voraphoj Nilaratanakul, Wanla Kulwichit <li> Scientific_Study_Excerpt: <p>This Lancet case report describes a near-fatal gastrointestinal bleeding incident linked to senna use in the context of anticoagulation. The authors discuss how severe diarrhea and changes in intestinal function from stimulant laxatives can modify absorption and vitamin K dynamics, altering INR and bleeding risk. Though rare, such reports justify INR monitoring and caution when stimulant herbal laxatives are used by patients on vitamin K antagonists.</p> </li> </ul> <h4> Narrow therapeutic index immunosuppressants (e.g., tacrolimus, cyclosporine)</h4> <ul> <li> Interaction_Details: Cassia-family herbal products may alter intestinal transporters (P-glycoprotein) or metabolism and can change blood levels of drugs like tacrolimus; a case showed a >2-fold increase in tacrolimus exposure after a Cassia product. <li> Severity: Severe <li> Recommendation: Avoid co-use; if exposure occurs, perform therapeutic drug monitoring (TDM) and consult transplant or clinical pharmacology specialists immediately. <li> Scientific_Study_Available: Yes <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/38657592/ <li> Scientific_Study_Title: Cassia angustifolia and tacrolimus interaction in a liver transplant patient, a case report. <li> Scientfic_Study_Authors: Iván Beltrá-Picó, Marcos Díaz-González, Ricardo Nalda-Molina, Amelia Ramon-Lopez, Sonia Pascual-Bartolomé, Cayetano F Miralles-Macià, María Rodríguez-Soler, Patricio Más-Serrano <li> Scientific_Study_Excerpt: <p>The 2024 case report detailed a liver transplant recipient who experienced a marked rise in tacrolimus blood concentrations after starting a Cassia angustifolia-based herbal product. The investigators documented a 2.8-fold increase in trough concentration and a 2.1-fold increase in AUC, suggesting impaired intestinal efflux or altered absorption possibly via P-glycoprotein modulation. The report warns that such interactions can cause dose-dependent toxicities (nephrotoxicity, neurotoxicity) and supports avoiding Cassia preparations in patients on critical immunosuppressants without intensive TDM.</p> </li> </ul>
